Current Report Filing (8-k)
February 04 2021 - 4:06PM
Edgar (US Regulatory)
0001595097
false
0001595097
2021-02-02
2021-02-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 2, 2021
CORBUS
PHARMACEUTICALS HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-37348
|
|
46-4348039
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
500
River Ridge Drive, Norwood, MA
|
|
02062
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (617) 963-0100
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class
|
|
Trading
Symbol
|
|
Name
of Each Exchange on Which Registered
|
Common
Stock, par value $0.0001 per share
|
|
CRBP
|
|
Nasdaq
Global Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
|
On
February 2, 2021, the Compensation Committee of the Board of Directors (the “Committee”) of Corbus Pharmaceuticals
Holdings, Inc. (the “Company”) approved equity compensation awards for the Company’s
executive officers, Yuval Cohen, Ph.D., Chief Executive Officer; Barbara White, M.D., Chief Medical Officer, Craig Millian, Chief
Commercial Officer and Sean Moran, Chief Financial Officer.
The
Committee approved a special award
of options to purchase shares of the Company’s common stock, par value $0.0001 per share, (the “Retention Options”)
in the following amounts: Dr. Cohen was awarded 956,500 Retention Options, and Dr. White, Mr. Millian and Mr. Moran were each
awarded 307,300 Retention Options. In addition to the Retention Options, the Committee also approved,
in the ordinary course, an
annual
award of stock options (the “2021 Annual Compensation Options”, together, with the Retention Options, the “Options”)
to each of Dr. Cohen, Dr. White, Mr. Milian and Mr. Moran in accordance with the terms of the employment agreements between each
of the executives and the Company in the following amounts: Dr. Cohen was awarded 956,500 2021 Annual Compensation Options, and
Dr. White, Mr. Millian and Mr. Moran were each awarded 307,300 2021 Annual Compensation Options. The Options were granted in accordance
with the terms of the Company’s 2014 Equity Compensation Plan (the “Plan”). The Options have an exercise price
of $2.58 and will vest 25% on the one year anniversary of the grant date and the remainder in equal monthly installments over
three years, with full acceleration of vesting upon a change in control (as defined in the Plan). In considering and approving
the awards of Options, the Committee considered general industry and industry peer group compensation information and recommendations
provided by the Committee’s independent compensation consultant.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CORBUS
PHARMACEUTICALS HOLDINGS, INC.
|
|
|
|
Dated:
February 4, 2021
|
By:
|
/s/
Yuval Cohen
|
|
Name:
|
Yuval
Cohen
|
|
Title:
|
Chief
Executive Officer
|
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Apr 2023 to Apr 2024